Abstract
Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion. A preliminary report suggested that adding all-trans retinoic acid (ATRA) to ESAs may improve their erythroid response, particularly in patients with high endogenous erythropoietin (EPO) level, and may improve other cytopenias. We conducted a prospective multicenter study of EPO-β and ATRA in anemic MDS patients with marrow blasts <10% and either previous ESA failure or relapse, endogenous EPO >500 U/l or other cytopenia(s) (absolute neutrophilic count <1.0 G/l or platelets <50 G/l). A total of 59 patients were evaluable after 12 weeks of treatment. The erythroid response rates according to IWG 2000 and 2006 criteria, respectively, were as follows: overall: 49 and 36%; patients with previous ESA failure (n=28): 43 and 32%; patients with endogenous EPO >500 U/l (n=18): 11 and 19%; patients transfused >2 red blood cells units/month (n=28) 43 and 39%. Only one neutrophil, but no platelet response, and no major side effect were observed. EPO-β–ATRA combination appears a possible therapeutic option in anemia of MDS having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve neutropenia and thrombocytopenia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hellstrom-Lindberg E, Malcovati L . Supportive care, growth factors, and new therapies in myelodysplastic syndromes. Blood Rev 2008; 22: 75–91.
Steensma DP, Tefferi A . Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc 2007; 82: 958–966.
Malcovati L . Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31 (Suppl 3): S2–S6.
Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104: 321–327.
Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E . Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803–811.
Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737–743.
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037–1046.
Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574–582.
Kelaidi C, Eclache V, Fenaux P . The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 2008; 140: 267–278.
Evans T . Regulation of hematopoiesis by retinoid signaling. Exp Hematol 2005; 33: 1055–1061.
Aul C, Runde V, Gattermann N . All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 1993; 82: 2967–2974.
Koeffler HP, Heitjan D, Mertelsmann R, Kolitz JE, Schulman P, Itri L et al. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood 1988; 71: 703–708.
Kurzrock R, Estey E, Talpaz M . All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993; 11: 1489–1495.
Ohno R, Naoe T, Hirano M, Kobayashi M, Hirai H, Tubaki K et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993; 81: 1152–1154.
Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266–1269.
Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005; 104: 101–109.
Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999; 78: 125–130.
Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 2005; 84: 389–394.
Zhang W, Zhou F, Cao X, Cheng Y, He A, Liu J et al. Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen. Leuk Res 2006; 30: 935–942.
Smith MA, Parkinson DR, Cheson BD, Friedman MA . Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839–864.
Stasi R, Brunetti M, Terzoli E, Amadori S . Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578–1584.
Ganser A, Maurer A, Contzen C, Seipelt G, Ottmann OG, Schadeck-Gressel C et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol 1996; 72: 237–244.
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C et al. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res 2008, [e-pub ahead of print].
Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86–93.
Lyons RM, Cosgriff T, Modi S, McIntyre H, Fernando I, Backstrom J et al. Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza(R)) in Patients with Myelodysplastic Syndromes (MDS). Blood 2007; 111: 819.
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J . Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505–2511.
Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006; 85: 174–180.
Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68–75.
Musto P, Falcone A, Carotenuto M, Catalano L, Cennamo A, Rotoli B . Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone? Blood 1994; 84: 1687–1688.
Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999; 84: 1058–1064.
Stasi R, Pagano A, Terzoli E, Amadori S . Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 1999; 105: 141–148.
Maurer AB, Ganser A, Seipelt G, Ottmann OG, Mentzel U, Geissler GR et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol 1995; 89: 449–456.
Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom AM, Emanuelsson E, Jadersten M et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 2005; 11: 6291–6299.
Schmidt-Mende J, Gogvadze V, Hellstrom-Lindberg E, Zhivotovsky B . Early mitochondrial alterations in ATRA-induced cell death. Cell death and differentiation 2006; 13: 119–128.
Acknowledgements
LA, PF and FD designed the study. RI, LA, HM, FC and PF collected and analyzed the data. RI drafted the paper. LA, HM, DV, EB, BS, NV, FS, OBR, AG, SC, XT, AS, MG, FB, AK, MCC, LL, GD enrolled patients.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Itzykson, R., Ayari, S., Vassilief, D. et al. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. Leukemia 23, 673–678 (2009). https://doi.org/10.1038/leu.2008.362
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.362
Keywords
This article is cited by
-
Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
Leukemia (2018)
-
Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy
Annals of Hematology (2016)
-
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
Leukemia (2014)